Followers | 129 |
Posts | 2150 |
Boards Moderated | 1 |
Alias Born | 12/27/2007 |
Wednesday, August 16, 2017 12:39:35 PM
Initiating Coverage June 26, 2017
http://www.lifescicapital.com/wp-content/uploads/Soleno.pdf
•Company expects to initiate pivotal Phase III clinical trial by year-end 2017; will take approximately 9-12 months to complete
Market Opportunity for PWS is Substantial.
While the lack of approved treatments for PWS alone make it difficult to assess the market, sales of Pfizer’s (NYSE: PFE)
Genotrop in (somatropin) can provide some insight despite being indicate for PWS, in addition to, growth failure due to growth hormone deficiency(GHD),Turner syndrome,idiopathic short stature,and small for gestational age.This product achieved its highest revenue in 2008,with worldwide sales of approximately $900 million.While somatropin has been proven to improve growth and body composition, it does not affect the key disease component of hyperphagia and use is associated with substantial risk. Soleno is developing DCCR for the treatment of PWS,to help address the unmet need of this patient population. To assess the potential of DCCR for PWS, we performed a scenario analysis, which indicates that annual sales could be in the range of $1.1 billion given a moderate price point and 50% market penetrance.
Very Strong Insider & institutional Ownership:
Vivo Ventures LLC 16 012 808
Forward Ventures Services LLC 7 251 728
Technology Partners 7 050 691
Aspire Capital Partners LLC 2 791 666
Ernest Mario, PhD 1 844 328
Oppenheim Asset Management Services SARL 574 853
Medical Strategy GmbH 503 305
Palo Alto Investors LLC 423 738
Sabby Capital LLC 233 938
The Bollard Group LLC 192 217
Recent SLNO News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:31:17 PM
- Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/09/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 09:28:56 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/06/2024 08:58:44 PM
- Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock • GlobeNewswire Inc. • 05/03/2024 02:32:12 AM
- Soleno Therapeutics Announces Proposed Public Offering of Common Stock • GlobeNewswire Inc. • 05/02/2024 08:01:37 PM
- Soleno Therapeutics Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to the Natural History of Prader-Willi Syndrome • GlobeNewswire Inc. • 04/30/2024 12:00:00 PM
- Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS) • GlobeNewswire Inc. • 04/29/2024 12:00:00 PM
- Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/19/2024 08:05:00 PM
- Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/08/2024 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:06:32 AM
- Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results • GlobeNewswire Inc. • 03/06/2024 09:05:00 PM
- Soleno Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/22/2024 01:00:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/31/2024 09:19:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 09:57:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/29/2024 10:47:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/29/2024 10:44:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/29/2024 10:42:33 PM
- Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 01/29/2024 09:05:00 PM
- Soleno Therapeutics Strengthens Leadership Team with Key Appointments • GlobeNewswire Inc. • 01/24/2024 01:00:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/17/2024 09:06:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 10:37:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 10:35:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 10:34:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 09:16:02 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM